Some examples are trastuzumab for metastatic Her2+ breast cancer; erlotinib and gefitinib for epidermal growth factor receptor (EGFR) mutated metastatic lung cancer; cetuximab and panitumumab for RAS-wild type metastatic colorectal cancer, in addition to several treatments used in hematological malignancies, which are not the focus of this report. This evidence concerns the gene EGFR and hematologic disorder.